The hereditary breast cancer susceptibility gene, BRCA2, is considered to be a tumor suppressor gene that may be involved in the cellular response to DNA damage. The transcript for this gene is cell cycle regulated with mRNA levels reaching a peak just before the onset of DNA synthesis. In order to de®ne the mechanisms by which BRCA2 is transcriptionally regulated, we have begun to study upstream regulatory sequences. In this report, we de®ne a minimal promoter region that has strong activity in human breast epithelial cells. Deletions of this sequence narrowed the strong basal activity to a region extending from 766 to +129 with respect to the BRCA2 transcriptional start site. This sequence demonstrated cell cycle regulated activity with kinetics similar to the endogenous transcript. Examination of the sequence revealed several consensus binding sites for transcription factors including an E-box, E2F and Ets recognition motifs. Electrohoretic mobility shift assays revealed speci®c protein binding to two sequences upstream of the start site; the palindromic Ebox and an Ets/E2F site. Site-directed mutagenesis of either of these sites reduced both the basal activity in log phase cells and the cell cycle regulated activity of the promoter. Mutational inactivation of both sites within the same construct eectively eliminated promoter activity. Antibodies to candidate transcription factors used in super shift experiments revealed speci®c interactions between the BRCA2 promoter and the basic region/helix ± loop ± helix containing USF-1 and 2 proteins and Elf-1, an Ets domain protein. Binding of these factors depended upon the presence of intact recognition sequences. The USF factors were shown to bind predominantly as a heterodimeric complex of USF-1 and 2 while Elf-1 bound the promoter when it was not occupied by USF. Co-transfection studies with USF proteins and the varicella zoster IE62 protein provide evidence for the involvement of endogenous and exogenous USF in the activation of the BRCA2 promoter. We propose that interactions between USF-1, USF-2 and Elf-1 play an important role in the transcriptional regulation of the BRCA2 gene.
Introduction
The second breast cancer susceptibility gene, BRCA2, was identi®ed by positional cloning techniques in 1995 from families who segregated an autosomal dominant allele on 13q12 (Wooster et al., 1995) . Germline mutations in BRCA2 account for only a small fraction of all breast cancers, however as many as 50% of sitespeci®c breast cancer families may harbor inactivating mutations in this putative tumor suppressor gene (Krainer et al., 1997) . Similar to BRCA1, acquired mutations in BRCA2 are relatively rare during neoplastic progression suggesting that both of these hereditary susceptibility genes confer an increased risk of acquiring other genetic alterations (Lancaster et al., 1996; Teng et al., 1996) . However, as with other tumor suppressor genes, inactivating mutations may not be the only mechanism by which their function is removed or altered during tumor evolution. Diminished gene expression by site-speci®c methylation or by changes in trans-acting factors may accomplish the same end as truncating mutations in the gene itself. Reduced expression of the BRCA1 transcript and increased methylation of the promoter have been observed in invasive breast cancers suggesting that this may be a functional control mechanism (Thompson et al., 1995; Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) . In one study on upstream sequences of the BRCA2 gene, no evidence of methylation was detected (Collins et al., 1997) , however the number of similarities between BRCA1 and 2 would suggest that expression of BRCA2 may also be targeted in sporadic cancer.
The function(s) of BRCA2 is not yet known but most experiments to date suggest that its gene product may play a role in the response to DNA damage (Zhang et al., 1998) . Preliminary studies on the subcellular localization of BRCA2 indicate that it is largely a nuclear protein . Yeast two-hybrid experiments have shown that there are two sites on the protein that can directly interact with the RAD51 protein, a eukaryotic homolog of the bacterial RecA repair protein that likely functions during meiotic and mitotic recombination, DNA repair, and chromosome segregation (Katagiri et al., 1998; Wong et al., 1997) . Inactivation of Rad51 in mice results in embryonic lethality characterized by severe growth retardation suggesting that it is also necessary for cellular proliferation (Lim and Hasty, 1996) . The results of BRCA2 knockout mouse experiments have now been published (Ludwig et al., 1997; Suzuki et al., 1997; Sharan et al., 1997; Connor et al., 1997; Patel et al., 1998) and provide further evidence for the role of BRCA2 in growth and response to DNA damage.
Expression patterns of BRCA2 also support its putative role in proliferative and DNA damage pathways. We and others have shown that BRCA2 mRNA is expressed in a cell cycle regulated manner (Vaughn et al., 1996a; Rajan et al., 1996; Bertwistle et al., 1997) .
The BRCA2 message is at low levels in G0 and early G1; peak levels are reached in late G1, just before entry into S phase and maintained at high levels through S and G2. This regulation is virtually indistinguishable from BRCA1 (Vaughn et al., 1996b) suggesting that both genes may be subject to similar control mechanisms. In addition, the expression of both genes is elevated in response to estrogen and after dierentiation in a mouse mammary epithelial model (Spillman and Bowcock, 1996; Rajan et al., 1996 Rajan et al., , 1997 . Even though a functional estrogen response element was identi®ed near the start of BRCA1 transcription (Norris et al., 1995) , a host of other evidence strongly implied that it is the proliferative eect of estrogen that indirectly induces expression of this gene (Marks et al., 1997; Phillips et al., 1997) . It is likely that estrogen induction of BRCA2 is also an indirect eect of its mitogenic activity (J Marks, unpublished data) .
We have begun to characterize sequences near the transcriptional start site of BRCA2 in order to de®ne cis acting sequences and trans acting factors that are important for the transcriptional regulation of this gene. In the current study, we have identi®ed the minimal promoter sequence capable of conferring high level cell cycle regulated transcriptional activity. This relatively small sequence recapitulated the same cell cycle regulation characteristic of the BRCA2 gene. Both the basal and cell cycle regulated activities were largely dependent upon two sequence elements in this promoter: (1) An E-box motif which is a consensus recognition site for the basic helix ± loop ± helix family of transcription factors; and (2) A sequence containing an overlapping Ets/E2F site. Furthermore, we have identi®ed the primary factors that bind to these elements as heterodimers of USF-1 and 2 to the Ebox and the Ets family member Elf-1 to the Ets site. Both of these factors form stable complexes with the promoter. We present evidence that overexpression of USF-1 and 2 are capable of inducing the activity of luciferase reporter constructs containing the BRCA2 core promoter region and that E1f-1 may have repressor activity. Finally, we demonstrate the ability of endogenous USF to mediate varicella zoster virus (VZV) IE62 transcriptional activation in an E-box and USF dependent manner.
Results

De®nition of the minimal BRCA2 promoter region
Based upon the location of the transcription start site and the genomic sequence from PAC 214K23 (derived from human chromosome 13q12 ± 13) containing the BRCA2 gene, two DNA fragments were ampli®ed and cloned. These fragments both contained the non-coding ®rst exon from BRCA2 and overlapped with each other (Figure 1 , designated Prom, 71470 to +129 and Int, 7423 to +975). These PCR products were cloned directly into the luciferase reporter vector, pGL3-basic and their sequences were veri®ed. Each clone was transfected into growing MCF-7 cells and luciferase activity was measured after 48 h. All transient assay values were normalized with a co-transfected CMV-b ± Figure 1 Schematic diagram of the region of the BRCA2 gene near the start of transcription showing the primary constructs tested for promoter activity. Two primary fragments were PCR ampli®ed from genomic DNA using sequence information derived from PAC 214K23. These were designated`Prom' and`Int'. These PCR products were cloned into the luciferase reporter vector, pGL3-basic, and their activities were measured by transient transfection into MCF-7 cells. All values were corrected for transfection eciency by measuring activity from a co-transfected CMV-bGal construct. The Int construct, which had the higher activity, was arbitrarily set at a value of 100. Restriction sites in Prom and Int were used to generate a set of smaller fragments that were tested in the same fashion. Each value represents the mean of at least two independent transfection assays performed in triplicate. Exon 1 is 187 bp, intron 1 is 1000 bp and exon 2 is 106 bp. This ®gure is not to scale galactosidase plasmid. Both of these constructs were highly active in this assay yielding luciferase activity greater than 40-fold over the background level obtained with the parental pGL3 vector alone (Prom at about 70% of Int, Figure 1) .
In order to narrow the minimal promoter region, two series of deletion constructs derived from Int and Prom were generated. The luciferase activity of each new construct was assessed by transient transfection into MCF-7 cells and these values are shown normalized to the Int fragment arbitrarily set at 100 ( Figure  1) . Results from the Int series of constructs showed that signi®cant activity was retained with deletions down to IntD6 spanning 766 to +269; this fragment contains all of exon 1 and a small amount of the ®rst intron. The Prom deletion series further narrowed the basal activity. High levels of luciferase expression were still generated with PromD3, a fragment spanning 766 to +129 which contains only part of the ®rst exon. Notably, constructs that lacked the region from 766 to 717 showed a dramatic reduction in basal activity (PrD4 and IntD7). The isolated intron 1 construct also showed low level activity in this assay (IntD2). Therefore, sequences from 766 to 717 appear to be critical for the basal activity of the BRCA2 promoter.
Cell cycle regulated activity of the minimal promoter constructs
To determine whether these sequences also contained cell cycle regulated elements that could recapitulate the regulation of the endogenous BRCA2 gene, these constructs were transfected into MCF-7 cells that were serum starved for 36 h and then released from this G 0 block by the addition of 20% serum. We reproducibly observed an increase in promoter activity from both the Prom and Int series of constructs that mirrored the release of the cell population into the S and G 2 /M phases of the cell cycle. Figure 2a shows a representative time course for the Prom series of promoter deletions over a 34 h release period. PromD2 in this and other similar experiments displayed the greatest transcriptional induction upon cell cycle release (between 3 ± 4-fold over starvation levels). This is comparable to the increase in steady-state levels of the BRCA2 mRNA that we observed in cultures that were harvested over the same time period Figure 2 Cell cycle regulated activity of the Prom series of BRCA2 promoter constructs. (a) Each construct was transfected into log growing MCF-7 cells. After 5 h, the transfection was stopped by the addition of RPMI containing 10% FBS. After 2 h of recovery, cells were starved by culturing in RPMI alone for 36 h. Triplicate cultures were harvested at each of the indicated time points and luciferase and b-gal activity were measured. The results shown are calculated by dividing the luciferase by the b-gal activity for each transfection. The 5' end of each of the reporter constructs is indicated next to the name, i.e.,`Prom' starts at 71470. All of the constructs share the same 3' end at +129. The inserted table shows cell cycle analysis of parallel cultures by propidium iodide staining and¯ow cytometry. (b) Expression of BRCA2 after release from starvation. MCF7 cells starved and released under the same conditions as those described above were harvested at identical time points and total RNA was isolated and electrophoresed on a 1% formaldehyde gel. The gel was electroblotted and probed with a BRCA2 cDNA. Ethidium bromide staining of the blot shows the ribosomal RNA levels as loading controls. (c) MCF7 cells transfected with PromD2 were treated with 2 mM hydroxyurea for 21 h and then released into media containing 20% FBS. Cells were cultured for the times indicated and then duplicate samples were harvested and analysed for luciferase and b-gal activities. Parallel cultures were harvested for cell cycle analysis by propidium iodide staining and¯ow cytometry (Figure 2b ) and also under similar conditions in our earlier studies (Vaughn et al., 1996a) . Each of the constructs containing this minimal sequence was also induced with entry into S phase, albeit to a lesser degree, while PromD4 containing only sequences from 717 to +129, showed no cell cycle regulation. The Int series demonstrated similar kinetics and cell cycle induction that also depended on the presence of sequences from 766 to 717 (data not shown).
In our previous work, we showed that the BRCA2 transcript reached its highest levels during S phase (Vaughn et al., 1996a) . In order to verify that the BRCA2 promoter fragment is controlled in similar manner, the PromD2 construct (having the highest cell cycle regulated activity, Figure 2a ) was transfected into MCF7 cells that were then synchronized by hydroxyurea treatment and released into 20% FBS. Duplicate sets of dishes were analysed for promoter activity and for cell cycle kinetics by propidium iodide staining and¯ow cytometry over a 34 h time period after release ( Figure 2c ). The activity of PromD2 in this experiment closely mirrors the fraction of cells in S phase in agreement with the endogenous levels of BRCA2 mRNA.
Sequence analysis of minimal promoter
Having de®ned a minimal promoter region with cell cycle regulated activity we began to characterize this region. Sequence analysis revealed sites with strong homology to known transcription factor binding motifs (Figure 3 ). In particular, there is a perfect palindromic E-box at 715 (CACGTG), a consensus Ets binding site core (GGAA, reading TTCC on the coding strand) overlapping with a potential E2F site at 745 (CTTCCGGG), and another possible E2F site at +85 (TTTGCGGC). Of these motifs, the E2F sites are most consistent with the type of cell cycle regulation observed. The upstream E2F motif is similar to one found in the human DNA polymerase a gene while the exon 1 sequence ®ts the consensus TTTSSSSS (S=C or G) (Slansky and Farnham, 1996) . There are no obvious TATA or CAAT boxes within the minimal promoter region and like many promoters, this one is GC rich (overall 63% in PromD2) and therefore contains several candidate SP1 sites.
Identi®cation of sequence-speci®c factor binding
In order to determine if there was speci®c binding to the putative transcription factor recognition sequences, a 264 bp 32 P-labeled DNA probe containing the minimal promoter (7119 to +128) was incubated with cell extracts prepared from log phase MCF-7 cells. Following electrophoresis of the protein/DNA complexes on a polyacrylamide gel, a primary complex was detected with single fainter bands visible above and below (Figure 4a ). To further evaluate the speci®city of these interactions, double-stranded oligomers were prepared and used as competitors in the electrophoretic mobility shift assays (EMSA). These competition assays were performed with a 50-fold molar excess of double stranded oligomers directed to the ®rst Ets/E2F site (Site 1), the E-box, and the second E2F site (Site 2). Each oligomer was also constructed with mutations that disrupted the consensus binding sequences. We observed a signi®cant reduction in the basal shift using the wild-type E-box competitor but not with a mutated palindrome. We also saw a slight reduction in the shift using the E2F Site 1 competitor, however an oligomer with a two base alteration in the consensus E2F sequence also demonstrated a weak competitive eect on the shift complex. The Site 2 mutant oligomer did not show any ability to compete in the EMSA. Combining the oligomers directed at both the Site 1 and E box sequences eciently competed the entire Figure 4 Gel shift analysis of BRCA2 promoter sequences de®ning the primary factor binding sites in the PromD2 fragment. (a) The PromD2 insert was gel-puri®ed, end-labeled with 32 P, and incubated with protein extract from log growing MCF-7 cells. Competitions were performed using a 50-fold molar excess of double-stranded oligomers (from 29 ± 37 bp in length) with the putative factor binding sites centered in the sequence. The Site 1 competitor was 29 bp and the mutant version altered the sequence CTTCCGGG to CTTCCaaG. The E-box competitor was 37 bp and the mutant version altered the sequence CGTCACGTGGC to CGaCtgcaGGC. The E2F Site 2 competitor was 30 bp and the mutant version altered the sequence TTTGCGGC to TTTGCaaC. In the lanes with 2 or 3 competing oligomers, each was used at 50-fold molar excess relative to the probe. The position of the speci®c shifted probe is indicated by *. (b) An alteration in the PromD2 probe was introduced at the E-box site (CACGTG changed to CtgcaG) and used as a probe as described above. Competition was performed with 50-fold excess of unlabeled wild-type or mutant Site 1 oligomer. The position of the speci®c shifted probe is indicated by * Figure 3 Sequence of the 323 bp PromD2 insert. The numbering system is based upon +1 as the start of transcription. The 5' end of PromD3 is also shown (its 3' end is the same as PromD2). PromD4 at 717 retains half of the E-box. Factor binding sites that are the subject of experimentation are indicated. An arrow (;) indicates the 5' boundary of the probe used in all electrophoretic mobility shift assays. The 3' end of the probe includes the remainder of this sequence and extends 17 bp into the polylinker of the cloning vector (pGL3-basic) shifted probe, indicating that the majority of transcription factor binding to this probe occurs at these two sites. We obtained identical results using protein extracted from a chemically immortalized cell line derived from normal breast epithelium (data not shown) .
While all binding could be eliminated using a combination of the Site 1 and E-box oligomers, the speci®city of the Site 1 competition was unclear since both the wild-type and mutant oligomers competed poorly. Therefore, we examined binding at this site in isolation by using a probe that contains an altered Ebox sequence created by site-directed mutagenesis. This probe was identical to the 264 bp probe used in Figure  4a except that the E-box core was changed from CACGTG to CtgcaG. Using this probe, the Site 1 oligomer eciently competed away the primary shifted complex while the mutant Site 1 sequence did not ( Figure 4b ). We only observed speci®c competition at Site 1 in the absence of an intact E-box suggesting some interaction between factors at these two sites.
For the Site 1 mutant oligomer, we changed the sequence from CTTCCGGG to CTTCCaaG, which disrupted the GC tract, a characteristic of E2F recognition sites, however the Ets core, TTCC, remained intact. Therefore, we also constructed the same oligomer changing the Ets core to TTaa. Competition experiments with this altered sequence gave identical results as the disrupted E2F site (data not shown). Collectively, these results show that the primary interactions between the BRCA2 promoter and factors present in breast epithelial cells occur at the E-box and the Ets/E2F site.
Mutations in identi®ed sites diminish basal and cell cycle regulated activity
To de®ne the contribution of the various putative transcription factor binding motifs, mutations in each of the four sites were introduced back into the PromD2 luciferase vector by site-directed mutagenesis and these mutant constructs were tested for their basal activity in log phase MCF-7 cells (Figure 5a ). Mutations in the Ebox, E2F Site 1, and the Ets site all reduced the basal activity of the promoter by approximately threefold while the E2F Site 2 mutant construct retained activity comparable to the wild-type PromD2. The E2F Site 1 and Ets mutations were directed to adjacent dinucleotides and each disrupted the consensus motifs for both factors. A double mutant construct was also generated in which both the Ets/E2F site and the E-box were mutated. This double mutation virtually inactivated the promoter in this assay, reducing luciferase activity almost to the level of the parental pGL3 vector.
The mutant constructs were then tested for their ability to be regulated in a cell cycle dependent manner. Cells were transfected, starved, and then released with 20% FBS. In a typical example of this experiment, the wild-type PromD2 construct yielded 3 ± 4-fold induction after serum release while the same fragments with altered E-box or Ets/E2F motif were induced less than twofold (Figure 5b ). The slightly lower induction of the Ets/E2F mutation versus the Ebox was reproducible in a number of experiments of this type. The double mutant demonstrated not only a very low activity in starved cells (time 0) but failed to induce at all through the cell cycle yielding a pro®le that was indistinguishable from the parental pGL3 vector. These results indicated that the two transcription factor binding sites identi®ed by gel shift analysis play a critical role in the regulation of the BRCA2 promoter.
USF and Elf bind to the BRCA2 promoter
The sequences of each of the two putative binding sites may be recognized by several dierent transcription factors. The Ets/E2F site could potentially bind one or more of the extended Ets or E2F family members while E-box motifs have been shown to interact with the bHLH containing family of proteins such as Myc and USF. To identify which of these factors, if any, can form complexes with the BRCA2 minimal promoter antisera raised against speci®c E-box, E2F, and Ets family members were added to the binding reactions. Of the Ets and E2F antibodies tested, only anti-Elf-1 generated a super shifted complex of decreased mobility (Figure 6a ). Antibodies to E2F1-5 failed to super shift the complex as did a pan-Ets antibody Figure 5 Basal and cell cycle regulated activity of the BRCA2 promoter with site-directed mutations in putative transcription factor binding sites. (a) The transcriptional activity of the wildtype and mutant constructs was measured by transfecting them into log growing MCF-7 cells and measuring normalized luciferase activity 48 h later. These data represent the mean plus or minus standard error of triplicate samples. (b) The cell cycle regulated activity of these constructs was measured the same way as described in Figure 2a . Each point again represents the mean from triplicate determinations (Ets1/2), an Ets-2 speci®c antibody and an antibody to Pea-3. The Ets antibodies have been tested in super shift assays and are functional on probes that are complexed to their cognate factors. The E2F antibodies were tested on the dihydrofolate reductase (DHFR) promoter using extracts from MCF-7 cells that were infected with adenoviruses expressing each of the E2F genes. In each case, a speci®c super shift complex was observed (data not shown).
Factors that can directly interact with the E-box palindromic sequence include the myc/max/mad and USF transcription factors. In super shift experiments, antibodies to each of these factors were incubated with the BRCA2 minimal promoter and MCF-7 protein extract. Of these, only the USF-1 antibody produced a super shifted band (Figure 6b ). The USF-1 antiserum blocked the formation of almost all the basal complex whereas the Elf-1 antibody only partially shifted this complex. Equal amounts of pre-immune mouse and rabbit serum had no eect on the bound complexes (data not shown).
Mutations alter transcription factor binding
To further characterize the sequences required for complex formation, we performed antibody-gel retardation assays on the BRCA2 minimal promoter sequence in which we had introduced either E-box or Ets mutations by site-directed mutagenesis. There are two highly related members of the human USF family which share extensive homology in the helix ± loop ± helix and the C-terminal leucine zipper domains. USF-1 and USF-2 can form homo and heterodimers on Ebox containing promoters (Sirito et al., 1992) . For experiments on E-box binding, we used antibodies that recognize USF-1 and USF-2 individually and do not cross-react (Figure 7a ). In the absence of antibody, the basal complex on the E-box mutant probe was signi®cantly reduced (lane 3) indicating that the majority of the basal shift is a complex with USF. Addition of a USF-1 speci®c antibody super shifted the complex on the wild-type (lane 1) and Ets mutant probes (lane 2) but failed to shift the E-box mutant (lane 3). The USF-2 antibody also shifted the wild-type and Ets mutant but not the E-box mutant. The addition of both USF-1 and 2 antibodies gave similar results but generated a single super shifted band that was dierent than either USF antibody alone indicating that USF-1 and 2 proteins bind the E-box as a heterodimeric complex. An analogous experiment was performed using an Elf-1 antibody ( Figure 7b ). As expected, the antibody produced a super shift complex on the wild-type probe (lane 1) and the E-box mutant (lane 2) but failed to shift the Ets mutant (lane 3). Finally, all three antibodies were used in the same super shift assay (Figure 7c ). The combination of USF-1 and 2 plus Elf-1 antibodies resulted in the formation of two shifted bands that represent a composite of the separate USF-1+2 and Elf-1 super shifts (in Figure 7c , lane 5 has the same bands as lane 4 plus lane 6). The lack of a novel super shifted band indicates that under these conditions, the BRCA2 promoter binds either the USF-1/2 heterodimer or Elf-1, but not both on the same molecule. In this experiment, there was little or no basal shift left after super shifting with all three antibodies providing further evidence that these are the primary transcription factors that directly contact the promoter fragment in this assay.
To investigate these interactions further, we obtained eukaryotic expression vectors for the USF-1, USF-2, and Elf-1 transcription factors. Each of these cDNAs Figure 7 Site-speci®city of transcription factor binding to PromD2. (a) The speci®city of the super-shift complex was demonstrated by incubating either the wild-type or mutant promoter probes with protein extract and USF-speci®c antibodies. In each series of three, the lane 1 probe is the wild-type PromD2, lane 2 is PromD2 with the Ets mutation and lane 3 is PromD2 with the E-box mutation. Antibodies to USF-1, USF-2, or both in combination were used. No sign of the super-shifted bands were apparent on the E-box mutant probe. (b) The same experiment was performed using an antibody to Elf-1. In this case, the lanes are 1, wild-type; 2, E-box mutant; 3, ets mutant. The Elf-1 antibody produced no visible super-shifted bands on the ets mutant probe. (c) On the wild-type PromD2, all three antibodies were used alone or in combination. Lane 1, no antibody; lane 2, USF-1; lane 3, USF-2; lane 4, USF1+2; lane 5, USF-1+2+Elf-1; lane 6, Elf-1. The super shifted antibody complexes are indicated Figure 6 Gel shift analysis to identify factors that interact with the BRCA2 minimal promoter. The PromD2 probe was incubated with protein extract from log growing MCF-7 cells in the presence or absence of antibodies directed against the transcription factors indicated. Alteration of the basal complex and appearance of new super shifted bands were present only in the Elf-1 and USF-1 lanes was either in a CMV vector or subsequently subcloned into the pcDNA backbone. We transfected these vectors into MCF-7 cells and harvested protein extracts 48 h later for use in gel shift assays using the same 264 bp minimal promoter as a probe (Figure 8a ). Transient expression of each of these transfected genes was veri®ed by immunoblotting these same extracts and comparing them to cells that had been transfected with pcDNA alone (Figure 8b) . In longer exposures of these and other blots, MCF-7 cells demonstrate easily detectable levels of both USF-1 and 2 (data not shown). Previous EMSA studies have shown that overexpression of USF-1 and USF-2 individually resulted in single intense bands that represent USF-1/ 1 or 2/2 homodimers (Sirito et al., 1992 (Sirito et al., , 1994 ) . These homodimer complexes have an altered mobility from the main shift complex seen in untransfected or pcDNA transfected cells. Mixing the two separately transfected extracts (USF1+2) failed to reform the USF-1/2 heterodimer on the promoter however, when the two genes were co-expressed in the same cells (USF1/2), the predominant complex was the heterodimer that migrated with an electrophoretic mobility intermediate to that of the individual homodimers. These data on the basal shift complex plus the super shift data above both indicate that the major complex formation on this promoter consists of a USF-1/2 heterodimer.
The same experiment was performed using an Elf-1 expression vector. Increased expression of the transfected gene was veri®ed by immunoblotting ( Figure 8b) . Again, overexpressing the appropriate transcription factor increased the amount of protein complexed probe (Figure 8a ). In this case, the position of the shifted band was not altered compared to the pcDNA control. Given that both Elf-1 and the USF-1/2 heterodimer appear to bind on independent molecules as evidenced by the composite super shift result from above (Figure 7c ), the band representing the basal shift complex contains comigrating probes that are bound to the USF-1/2 heterodimer and Elf-1. Further, overexpression of USF-1 and 2 reduced the amount of probe detected by Elf-1 antibodies (data not shown) again suggesting that the factors bound to these elements may act in concert.
Response of BRCA2 core promoter to speci®c exogenous transcription factors
In order to address the impact of USF-1, USF-2, and Elf-1 expression on BRCA2 promoter activity in MCF-7 cells, co-transfection experiments were carried out. The BRCA2 promoter construct driving the luciferase reporter gene (PromD2) was co-transfected together with expression constructs for USF-1, USF-2 and Elf-1 into MCF-7 cells. PromD2 constructs with mutations in the transcription factor binding sites were used in each experiment as controls for the speci®city of the response. While USF-1 and 2 did induce the activity of PromD2, they were also able to induce the same construct carrying a mutated E-box, albeit to a lesser degree (Figure 9a ). The combination of USF-1 and 2 transfected together had slightly more eect than either factor transfected alone. Elf-1 repressed expression from PromD2 about twofold and had no eect on the Ets mutant construct. Similar results were obtained with co-transfection experiments in another breast cancer cell line ± SKBR3 cells (data not shown).
In order to de®ne further the role of USF in the regulation of the BRCA2 promoter, we exploited the known interaction between USF proteins and the varicella-zoster virus (VZV) IE62 protein. IE62 has been shown to cooperate with USF to activate promoters containing USF binding sites (Meier et al., 1994) . This cooperation requires the DNA-binding and transactivation domains of USF and can be inhibited by USF dominant negative mutant proteins (Meier et al., 1994; In this experiment, USF1 and 2 protein levels were increased by a factor of approximately 25 over the pcDNA control. In other experiments, the increase ranged from 5 ± 30-fold. USF-1 and USF-2 migrate with an apparent molecular weight of approximately 44 kd while Elf-1 migrates at approximately 95kd (indicated by *) Qyang et al., 1999) . We co-transfected varying amounts of the IE62 gene controlled by the CMV promoter with either PromD2 or PromD2 containing a mutation in the E-box (Figure 9b ). IE62 activated transcription of PromD2 12-fold over the basal level. In contrast, IE62 increased the activity of the E-box mutant by less than a factor of 2, indicating that the eect depends upon an intact USF recognition site. The addition of cotransfected USF-1 or USF-2 with IE62 produced no additional increase in the activity of PromD2 suggesting that endogenous levels of USF are sucient for a maximal eect (data not shown). To verify that IE62 was acting through USF, we utilized two dominant-negative USF constructs; pUSF-2DB which lacks the DNA binding domain and pUSF-2DN which lacks the Nterminal sequences required for transactivation (Luo and Sawadogo, 1996) . Ectopic expression of these mutants sequesters endogenous USF in inactive complexes. Cotransfection of these mutants decreased transcriptional activation by IE62 to approximately 50% of the activity seen with IE62 alone (Figure 9c ). Activation by IE62 in the presence of USF2DB was restored by co-transfecting either USF-1 or USF-2, con®rming that the IE62 eect is indeed mediated through USF proteins (Figure 9c ). These experiments indicate that endogenous and exogenous USF proteins are involved in the IE62 response of the BRCA2 promoter further supporting the role of the USF proteins in the regulation of this gene.
Discussion
In this report, we provide an initial characterization of the BRCA2 promoter. From the transcription initiation site that was previously identi®ed, we cloned and analysed sequences ranging from 71470 to +975 which span the ®rst non-coding exon and intron 1. Deletion analysis showed that most of the promoter activity was localized to a sequence from 766 to +129. This sequence was also the minimal region necessary to recapitulate the same type of cell cycle regulation that we observed for the endogenous BRCA2 gene (Vaughn et al., 1996a) . There are no discernible TATA or A/Trich elements near the start of transcription so we would classify this as a TATA-less promoter. Within this narrowly de®ned region there are several good consensus transcription factor binding sites including an E-box, an Ets/E2F site and an SP1 site. The palindromic E-box is centered at 718, the Ets/E2F site is at 758, and the SP1 site is at 76. The proximity of these sites to the start of transcription would indicate that they are signi®cant controlling elements.
Several lines of evidence presented in this paper indicate that the Ets/E2F sequence and the E-box are the predominant sites that control both basal and cell cycle regulated transcription. Using a relatively large probe extending from 7195 to +129, we were able to compete all speci®c binding using synthetic oligomers directed to these two sites. Oligomers containing mutations in the putative factor recognition sequence had a diminished capacity to compete in a gel shift assay thereby demonstrating the site-speci®c nature of the complexes. Mutations in these sites reduced both the basal activity of the promoter and the cell cycle regulated activity, indicating that these sites play an Figure 9 (a) Eect of transcription factor overexpression on the BRCA2 promoter. MCF7 cells were transfected with PromD2, Ebox mutant and Ets mutant reporter plasmids, together with the indicated transcription factors. Luciferase activities were determined in triplicate cultures 48 h after transfection and normalized against corresponding b-gal activities. Values depicted in the graph represent fold induction over the same reporter constructed cotransfected with pcDNA. The E-box mutant was used for USF transfections and the Ets mutant was used for the Elf-1 transfection. (b) Transcriptional activation by IE62 in MCF7 cells. Cells were transfected with the indicated BRCA2 reporter plasmids together with increasing amounts of pCMVIE62. The corresponding empty vector was included in each transfection to maintain the same ®nal total DNA content. Luciferase activities were determined in triplicate cultures 48 h after transfection and normalized against corresponding b-gal values. (c) Eect of USF dominant-negative mutants on IE62 activity in MCF7 cells. Cells were transfected with PromD2 together with the indicated expression vectors and the resulting luciferase values 48 h after transfection were normalized against pRLCMV using a dual luciferase activity procedure essential role in the activity of the promoter. Engineering both mutations into one reporter construct virtually eliminated the activity of the promoter in transient transfections and its ability to speci®cally bind factors in gel shift assays. We also demonstrated identical speci®city to these two sites using both the breast cancer cell line MCF-7 as well as a chemically immortalized normal mammary epithelial line . From these data, the E-box and Ets/E2F sites became the focus of our eorts to de®ne the DNA binding factors that regulate the BRCA2 promoter.
Both of these sites can interact with a number of dierent transcription factors, some of which would appear to be more likely candidates when considering the known cell cycle regulation of the gene. For the Ebox, the Myc family members have been shown to induce genes in G 1 , however the very late G 1 induction of BRCA2 is not normally associated with c-myc regulation. Our data point strongly to a USF heterodimer being the predominant factor that binds to this particular E-box. USF was originally identi®ed as a human cellular factor which bound to an E-box motif in the adenovirus major late promoter and which stimulated transcription in in vitro assays (Carthew et al., 1987; Miyamoto et al., 1985; Sawadogo and Roeder, 1985) . Bendall and Molloy (1994) performed a detailed analysis of E-box¯anking sequences in order to identify the determinants for Myc/Max versus USF speci®city. Based upon their study, we predicted that the E-box in the BRCA2 promoter would bind Max/ Max homodimers and USF dimers equally well. However, we found no evidence for Max association with the BRCA2 E-box and transient transfection of this factor had little or no eect on the isolated promoter (data not shown). Like BRCA2, the CAD gene is induced in late G 1 and also has a critical E-box that is essential for this regulation (Miltenberger et al., 1995) . Both USF and Myc/Max can bind to the CAD E-box, however the G 1 /S induction is mediated by replacing USF with a Myc/Max heterodimer (Boyd and Farnham, 1997) . This mode of regulation does not seem to apply to BRCA2 since we found no evidence that either Myc or Max can bind to or in¯uence its promoter element. USF has also been implicated in the cell cycle regulation of the cyclin B1 gene, however it is induced during the G 2 phase via an increase in USF ± DNA binding activity (Cogswell et al., 1995) . This paradigm fails to account for the temporal regulation of BRCA2 by USF. Our results show that the predominant form of USF that binds to the BRCA2 E-box is the 1/2 heterodimer. In EMSA experiments, most of the shift complex was recognized by both USF-1 and USF-2 antibodies. We found no obvious dierences in dimer composition using cellular protein extracts from dierent phases of the cell cycle although subtle changes in the ratio of homo to heterodimers would have been dicult to detect.
Overexpression of USF-1 and USF-2 only modestly activated the BRCA2 promoter. Given the clear indications of speci®c USF and Elf binding to the BRCA2 core promoter region, it was somewhat surprising that this was not re¯ected by more dramatic eects on the promoter function. Furthermore, the signi®cant decrease in promoter activity accompanying mutations in the E-box and Elf-1 sites demonstrates the functional signi®cance of these two transcription factor binding sites. MCF-7 cells express a high level of endogenous Elf-1 protein which we could not signi®cantly enhance (only 2 ± 3-fold) by transient transfection of CMV-Elf. This may explain the lack of a dramatic eect on PromD2 transcriptional activity, as the Ets binding site could be saturated with endogenous Elf protein. The functional interaction of USF-1 and USF-2 on this promoter has also been dicult to characterize. The ability of these factors to transactivate PromD2 (albeit weakly in MCF-7 cells) is not solely dependent on the presence of an intact Ebox. A report by Desbarats et al. (1996) documented a similar situation with the rat prothymosin-a intron enhancer element that contains a critical E-box; ectopic expression of USF was shown to equally transactivate reporter plasmids carrying this sequence with the Ebox either intact or mutated, indicating that activation did not occur entirely through the E-box element. In addition, activation by USF has been reported for a number of other promoters either lacking an E-box or containing a mutated E-box (Du et al., 1993; Li et al., 1994; Meier et al., 1994) . Our results are consistent with these previous studies and suggest that USF may interact directly and indirectly with the BRCA2 core promoter region. Alternatively, overexpression of USF may be modulating the level or activity of other proteins or basal transcription factors that mediate the activity of the BRCA2 promoter in these cells.
Transcriptional regulation involves communication between activators bound to distal enhancer control elements, and general factors acting through core promoter elements. With respect to core promoter functions, the mechanism of transcription initiation is well characterized in promoters with TATA elements (Roeder, 1996) , whereas less is known about comparable mechanisms that exist in TATA-less promoters. In some promoters which lack an apparent TATA box, (as is the case for BRCA2) initiator elements (Inr) have been de®ned and shown to be functionally important in directing basal transcription (Javahery et al., 1994; Ayer and Dynan, 1988; Smale and Baltimore, 1989) . A variety of proteins have been demonstrated or inferred to recognize the Inr including USF (Smale, 1997) . Whether there is an Inr in the BRCA2 promoter remains to be determined, but the unique ability of USF to act through two distinct promoter elements (the E-box and Inr) could provide another level of speci®c control on the BRCA2 promoter which we have yet to de®ne. Furthermore, selective interactions of USF-1 with the initiator-binding protein TFII-I (Roy et al., 1991) , with TBP-associated factor TAFII55 (Chiang and Roeder, 1995) and most recently with Ets-1 (Sieweke et al., 1998) have been demonstrated. Both TFII-I and Ets-1 were shown to act synergistically with USF-1 to activate transcription from the adenovirus major late promoter and the distal enhancer region of the HIV-1 LTR respectively.
We were able to show signi®cant activation of the promoter by a viral USF co-activator, the VZV IE62 protein. IE62 has only weak DNA binding activity that demonstrates little sequence speci®city (Tyler and Everett, 1993) . We demonstrate that the activation with IE62 required an intact E-box and was inhibited by two dierent dominant negative USF-2 constructs. In addition, inhibition by the USF-2 mutants could be reversed by the addition of wild-type USF. However, IE62 mediated activation did not require nor was it enhanced by the addition of exogenous USF expression indicating that endogenous USF protein does interact with the E-box. It would also suggest that the endogenous levels of USF are sucient to fully mediate activation through this element. Further, this may oer an explanation for why we were unable to signi®cantly activate the promoter via exogenous USF.
The other primary factor-binding site that we uncovered was the Ets/E2F consensus sequence. A number of factors could potentially recognize this site of which the most consistent with the late G 1 regulation of BRCA2 is the E2F family. There are two potential E2F sites within the promoter region, one at 738 and the other in exon 1 at +85. This second site appeared inconsequential since mutations in this second putative E2F site had no eect on the promoter activity in transient assays and no speci®c binding could be detected. The upstream site, however, was clearly signi®cant as evidenced by site-directed mutations and factor binding in gel shift assays. Using a series of approaches, we failed to demonstrate any E2F interaction at this sequence (data not shown).
Elf-1 is considered to be a lymphoid-speci®c transcription factor with demonstrated binding to genes regulated during T cell activation including the T cell receptor, the IL-2 receptor, and the HIV-2 LTR (Rellahan et al., 1998; Thompson et al., 1992; . We found high levels of the Elf-1 protein in nine of nine breast epithelial cell lines examined (not shown) suggesting that it has a broader distribution than heretofore described. What prompted our examination of Elf-1 in the BRCA2 promoter system was the report that Elf-1 (like the E2F's) is a retinoblastoma-associated protein (Wang et al., 1993) . Since it can be bound to underphosphorylated Rb, Elf-1 may be released and become available for binding late in G 1 after Rb becomes highly phosphorylated, thereby providing a transcriptional stimulus with kinetics similar to E2F. Our ®ndings do indeed suggest that the Elf-1 site in the BRCA2 promoter interacts with a positively acting factor since mutating the sequence lowered both the basal and cell cycle regulated activity of the promoter. This mutation also resulted in a failure of the promoter to complex with Elf-1 in EMSA's. However, overexpression of Elf-1 repressed the promoter in transient assays. Elf-1 binding resulting in transcriptional repression does have a precedent. The IL-2 receptor a gene utilizes an upstream enhancer element that contains an Elf-1 site that overlaps and interferes with binding and transcriptional activation at a Stat5 recognition sequence (Lecine et al., 1996) . In a sense this situation may be similar to what we see occurring on the BRCA2 promoter. The gel super-shift assays suggest that Elf-1 and USF may interact with the promoter alternatively. Therefore, occupation by Elf-1 may prevent USF binding (and vice versa) . The fact that mutation of the Elf-1 site reduced the promoter activity suggests that either there is some cooperativity between the E-box and Elf-1 site or that an alternative factor binds to the Elf site when the E-box is occupied. USF binding to the E-box was indistinguishable on the wildtype promoter and the Elf-1 mutated promoter, both in the level of binding and in the dimer composition. This would suggest that if there is cooperativity between the two sites, it does not aect the secondary complex between DNA and USF but perhaps perturbs higher order protein/protein complexes. Regarding the other possibility, the existence of an alternative factor that binds to the Elf-1 site cannot be excluded at this time.
In summary, the present study provides the ®rst characterization of the BRCA2 promoter. We have de®ned the minimal core region necessary for promoter activity, as well as the region required for cell cycle regulated activity in MCF-7 cells. We have identi®ed proteins that are capable of binding the core region, and determined the functional importance of several transcription factor binding sites. We also show evidence of modest transactivation of the promoter by USF-1 and USF-2 and repression by Elf-1. Furthermore, we demonstrate the ability of USF to mediate transcriptional activation of the BRCA2 promoter by IE62 in an E-box and USF dependent fashion. These preliminary ®ndings set the stage for a more detailed analysis of the molecular interactions that may contribute towards a clearer understanding of the transcriptional regulation of this important tumor suppressor gene.
Materials and methods
Plasmid constructions
The BRCA2 transcriptional start site was previously identi®ed by a modi®ed 5' RACE protocol . The BRCA2 genomic region in PAC.214K23 was used as a template for PCR reactions with primers designed using genomic sequence available in the public domain (Washington University Genome Center Web site, ftp:\\genome.wustl.edu). The following two pairs of primers were used to generate two fragments that span the start of transcription: Forward, 5'-CACTAGCTAGCGTCATCCAC-AACCACACAC-3'; Reverse, 5'-CGCTACTCGAGCCTAC-GATATTCCTCCAAT (5769 ± 7367) and Forward, 5'-AGT-CAGCTAGCCTAGAATTCAAACCTGGGC-3'; Reverse, 5'-ACCGCCTCGACACAAATCTGTCCCCTCAC (6815 ± 8213).
These PCR products were cloned directly into the luciferase reporter plasmid pGL3 basic (Promega), cut with NheI and XhoI, to create pGL3-Prom and pGL3-Int respectively. The identity and ®delity of the inserts were veri®ed by sequence analysis using the automated ABI377 Sequencer and Perkin-Elmer dye termination kits.
Internal deletion mutants of pGL3-Int and Prom were created by digesting the vectors with various unique enzymes, blunting with Klenow if necessary, and ligating to generate two series of deletion constructs as follows: pGL3-Int was cut with (a) NheI/StuI to give pGL3 IntD1 retaining 1041 bp of 
Site directed mutagenesis
Site directed mutants of pGL3 PromD2 were generated using the Quick Change site directed mutagenesis kit (Stratagene): the E-box (see Figure 3) was changed from CACGTG to CTGCAG; mutant bases indicated by boldface type; the E2F Site I (Figure 3 ) was changed from CTTCCGGG to CTTCCAAG; the E2F Site II (Figure 3 ) was changed from TTTGCGGC to TTTGCAAC; the GGA core sequence of the Ets site (antisense strand, Figure 3 ) was changed from TGACTTCCGG to TGACTTAAGG. A double mutant was created by starting with the PromD2-E-box mutant and subsequently introducing the E2F Site I mutation. All base substitutions were veri®ed by DNA sequencing.
Cell culture and transient transfections
MCF-7 cells, a human breast cancer cell line, were maintained in RPMI 1640 plus 10% fetal bovine serum (FBS). One day prior to transfection, cells were seeded into 12-well plates. Transfections were carried out in triplicate using Lipofectin (Life Technologies) according to the manufacturer's instructions; each well received a total of 1.5 ± 2 mg DNA ± 1 mg BRCA2 luciferase reporter plasmid, 500 ng CMV-driven b-galactosidase expression plasmid (or a renilla luciferase vector, pRLCMV (Promega)) and carrier DNA (pGL2 basic). Luciferase assays were performed 48 ± 60 h following transfection using a luciferase reporter assay system (Promega). Luciferase values were corrected for transfection eciency by normalization to b-galactosidase values or the renilla luciferase activity using the dual luciferase system. For co-transfections, cells received 200 ng of the reporter DNA, 0.2 ± 1.0 mg of the expression plasmid and carrier DNA. For transfection and synchronization experiments, cells were allowed to recover for 2 h after the transfection in RPMI with 10% FBS; this complete medium was then replaced with starvation medium (RPMI 1640, phenol red free, 0% FBS). After 36 h, the cells were stimulated to reenter the proliferative cell cycle by replacing the starvation medium with medium containing 20% FBS. Cells were harvested at speci®c times following serum stimulation and assayed for luciferase and b-gal activity. The progression of cells through the cell cycle during these experiments was monitored by¯ow cytometric analysis of replicate samples of propidium iodide-stained cells as previously described (Vaughn et al., 1996b) . Each transfection experiment was repeated at least twice with triplicate samples each time.
In some experiments, a chemically immortalized breast epithelial cell line designated in our laboratory as 26NC was used . These cells were maintained in DFCI-1 and starved in DFCI-3 (Band and Sager, 1989) .
RNA isolation and analysis
At each time point, cells from a 60 mm plate were lysed in 1 ml of Trizol (Gibco/BRL) for 5 min. Lysates were stored at 71008C. RNA was isolated by methods recommended for the Trizol reagent by Gibco/BRL. 7 mg of total RNA from each sample was loaded on a 1% formaldehyde-agarose gel, electrophoresed, electroblotted, and probed for BRCA2 as previously described (Vaughn et al., 1996b) .
Eukaryotic expression plasmids
pCMV-USF1 and pCMV-USF2 were made by subcloning USF-1 and USF-2 cDNAs from pSV-USF-1 and pSV-USF-2, kind gifts from Dr M Sawadogo (MD Anderson Cancer Center, University of Texas, TX, USA), into pcDNA3.1. USF-1 was cloned into EcoRI/ApaI sites in the polylinker; USF-2 was cloned into EcoRI/BamHI. pCMV-Elf1 was a kind gift from Dr I Leiden (University of Michigan Medical Center, Ann Arbor, MI, USA). pUSF2-DB and pUSF2-DN were also kind gifts from Dr M Sawadogo. pCMVIE62 was a kind gift from Dr S Straus (NIAID, NIH, Bethesda, MD, USA).
Electrophoretic mobility shift assays (EMSA)
Whole cell extracts were prepared from MCF-7 cells that were either starved, in log phase, at various times following synchronization and serum release, or from cells transfected with expression plasmids. Extracts were prepared using the following method. Cells were washed once with ice cold PBS, harvested by scraping, centrifuged at 2000 g for 5 min at 48C, and the pellets resuspended in 10 volumes of whole cell lysis buer containing 10% glycerol, 50 mM HEPES (pH 7.9), 250 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP40, 0.4 mM NaF, 0.4% sodium vanadate, 0.5 mM PMSF, 0.1 mM DTT, 2 mg/ml aprotonin, 1 mg/ml pepstatin, and 2 mg/ml leupeptin. Resuspended pellets were incubated on ice for 30 min and cellular debris was removed by centrifugation. Protein concentrations were determined by the Bradford assay and extracts were stored in small aliquots at 7708C. DNA probes were generated by cutting PromD2 with ApoI and HindIII, gel purifying the 264 bp fragment containing the minimal promoter, and ®lling in one nucleotide from each restriction site with a [ 32 -P]d-ATP using Klenow. In some experiments, double-stranded oligomers were used as probes. These oligomers were synthesized with 2 base 5' overhangs on each end that were ®lled in with [a-
32 P]d-ATP using Klenow to generate labeled probe. EMSA assays were performed as described by Ikeda et al. (1996) .
Competition experiments were performed by adding double-stranded DNA oligomers at a 50-fold molar excess to the ®rst incubation. Competitor DNAs used were: For super shift assays, 1 ml of speci®c or control antisera was added to the binding reactions after the 15 min incubation with labeled probe and the incubation was continued at 228C for 15 min.
Antisera and immunoblots
Immunoblots were carried out as previously described . The monoclonal Elf-1 antibody, 5A3 was a kind gift from Dr J Leiden; a polyclonal Elf-1-speci®c rabbit antisera was obtained from Santa Cruz. All other antisera were from Santa Cruz.
